Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitis
Glenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 14, 2022 Category: Pharmaceuticals Source Type: news
REACT Study: Allergy Therapy Improves Asthma Long Term REACT Study: Allergy Therapy Improves Asthma Long Term
A large European cohort study reports that therapy for allergic rhinitis may enable people who also have asthma to use fewer asthma medications.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 20, 2021 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
What Is the Difference Between Allergy and Hay Fever?
Title: What Is the Difference Between Allergy and Hay Fever?Category: Diseases and ConditionsCreated: 12/10/2021 12:00:00 AMLast Editorial Review: 12/10/2021 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - December 10, 2021 Category: Allergy & Immunology Source Type: news
People with allergic conditions including hay fever and a runny nose have a lower risk of COVID-19
A new study from Queen Mary University of London found that people with allergic conditions such as hay fever, rhinitis, atopic diseases and asthma had an up to 40% lower risk of COVID-19 infection. (Source: the Mail online | Health)
Source: the Mail online | Health - December 3, 2021 Category: Consumer Health News Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
People with allergies may be more likely to have mental health disorders, study finds
People with asthma, atopic dermatitis and hay fever may be more likely to suffer from depression, anxiety, bipolar disorder and other mental health disorders, a study published by Clinical and Experimental Allergy found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 6, 2021 Category: Consumer Health News Source Type: news
Allergies including asthma and hay fever not linked to mental health traits
Allergic diseases such as asthma, atopic dermatitis and hay fever do not cause the onset of mental health conditions or vice versa, according to the findings of a new University of Bristol-led study published today (6 October) in the journal Clinical and Experimental Allergy. (Source: University of Bristol news)
Source: University of Bristol news - October 6, 2021 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences, Faculty of Life Sciences, Faculty of Life Sciences, School of Psychological Science; Press Release Source Type: news
Antihistamine poisoning: Seven warning signs you've taken too much hay fever medication
HAY FEVER can cause itchy, red watery eyes, sneezing fits, and a sore throat. If you find that taking an antihistamine isn't solving the problem, you might be tempted to try alternative methods. (Source: Daily Express - Health)
Source: Daily Express - Health - August 8, 2021 Category: Consumer Health News Source Type: news
Thunder fever warning: Common symptoms to look out for - thunderstorms to hit UK this week
THUNDER FEVER is a term for hay fever whereby symptoms are made worse by thunderstorms - and a storm is on its way to cause problems for the UK's 30 million hay fever sufferers this weekend. (Source: Daily Express - Health)
Source: Daily Express - Health - July 23, 2021 Category: Consumer Health News Source Type: news
Is hay fever on the rise? – podcast
After 18 months of life being at a near standstill, Science Weekly ’s Shivani Dave found a lot of their conversations with friends turned to the severity of hay fever this year. Many claimed their allergies had never been worse. Shivani Dave asks horticulturist, Thomas Ogren, whether hay fever symptoms have become more severe in recent timesContinue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 1, 2021 Category: Science Authors: Presented and produced by Shivani Dave Tags: Hay fever Allergies Science Source Type: news
Hear RPS England Chair Thorrun Govind speak to the BBC about hay fever and cetirizine shortages
RPSEnglish Pharmacy Board Chair Thorrun Govind featured on BBC Radio 5 Live and BBC radio stations across the country yesterday, June 24, after pharmacists reportedshortages of cetirizine.
The antihi (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 25, 2021 Category: Drugs & Pharmacology Source Type: news